Adocia Net Change in Intangible Assets 2016-2024 | ADOCY

Adocia net change in intangible assets from 2016 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Adocia Net Change in Intangible Assets 2016-2024 | ADOCY

Adocia net change in intangible assets from 2016 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$241.7B
Amgen (AMGN)$155.8B
Gilead Sciences (GILD)$149.1B
Vertex Pharmaceuticals (VRTX)$101.5B
Bristol Myers Squibb (BMY)$97.4B
CSL (CSLLY)$86.1B
GSK (GSK)$79.8B
Regeneron Pharmaceuticals (REGN)$59.5B
Alnylam Pharmaceuticals (ALNY)$56.7B
Argenex SE (ARGX)$39.6B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.5B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Exact Sciences (EXAS)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$8B